Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event.
Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination.
Tumor-like multiple sclerosis.
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
Laquinimod CHMP/EMA opinion
A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment.
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
Tangier's disease: An uncommon cause of facial weakness and non-length dependent demyelinating neuropathy.
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Recommendations for the management of multiple sclerosis relapses.
Capture, crawl, cross: the T cell code to breach the blood-brain barriers.
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Evaluating medically at-risk drivers: a survey of assessment practices in Canada.
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Scrub typhus with longitudinally extensive transverse myelitis.
Genome-wide pathway analysis of a genome-wide association study on multiple sclerosis.
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity

Pages